Hederagenin inhibits PDE9A and attenuates cardiac hypertrophy by activating the cGMP-PKG pathway, suggesting potential heart failure therapy.
Hederagenin acts as a novel PDE9A inhibitor to attenuate cardiac remodeling, offering a potential therapeutic strategy for heart failure.
Absolute Event Rate: 0% vs 0%
Our study suggested that HED, as a novel PDE9A inhibitor, ameliorated cardiac hypertrophic response by activating the cGMP-PKG signaling pathway, presenting a potential therapeutic strategy for heart failure.
Chen et al. (Thu,) reported a other. Hederagenin inhibits PDE9A and attenuates cardiac hypertrophy by activating the cGMP-PKG pathway, suggesting potential heart failure therapy.